You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTheophylline
Accession NumberDB00277  (APRD00082, DB09359)
TypeSmall Molecule
GroupsApproved
Description

A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.

Structure
Thumb
Synonyms
1,3-dimethyl-7H-purine-2,6-dione
1,3-dimethylxanthine
Theophyllin
Theophylline anhydrous
Theophylline, anhydrous
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Elixir De Theophyllineelixir80 mgoralLaboratoire Atlas Inc1985-12-31Not applicableCanada
PMS-theophylline Elixirelixir80 mgoralPharmascience Inc1983-12-31Not applicableCanada
Pulmophylline Elxelixir80 mgoralLaboratoire Riva Inc1979-12-31Not applicableCanada
Quibron T SR Tab 300mgtablet (extended-release)300 mgoralBristol Labs Division Of Bristol Myers Squibb1982-12-312004-08-05Canada
Slo-bid 100capsule (sustained-release)100 mgoralAventis Pharma Inc1987-12-312003-07-22Canada
Slo-bid 200capsule (sustained-release)200 mgoralAventis Pharma Inc1987-12-312003-07-22Canada
Slo-bid 300capsule (sustained-release)300 mgoralAventis Pharma Inc1987-12-312002-07-29Canada
Slo-bid 50capsule (sustained-release)50 mgoralAventis Pharma Inc1988-12-312003-07-22Canada
Teva-theophylline SRtablet (extended-release)300 mgoralTeva Canada Limited1998-04-16Not applicableCanada
Teva-theophylline SRtablet (extended-release)200 mgoralTeva Canada Limited1996-12-19Not applicableCanada
Teva-theophylline SRtablet (extended-release)100 mgoralTeva Canada Limited1998-04-16Not applicableCanada
Theo ERtablet (extended-release)600 mgoralAa Pharma Inc2011-06-23Not applicableCanada
Theo ERtablet (extended-release)400 mgoralAa Pharma Inc2011-06-23Not applicableCanada
Theo-dur 100 mgtablet (extended-release)100 mgoralAstrazeneca Canada Inc1979-12-312001-11-21Canada
Theo-dur 200 mgtablet (extended-release)200 mgoralAstrazeneca Canada Inc1979-12-312003-04-29Canada
Theo-dur 300 mgtablet (extended-release)300 mgoralAstrazeneca Canada Inc1979-12-312003-04-29Canada
Theo-dur 450 mgtablet (extended-release)450 mgoralAstrazeneca Canada Inc1988-12-312001-07-30Canada
Theo-SR 300 Srt 300mgtablet (extended-release)300 mgoralRhone Poulenc Rorer Canada Inc.1987-12-311999-08-12Canada
Theolairliquid80 mgoralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada
Theolair SR Tab 200mgtablet (extended-release)200 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theolair SR Tab 250mgtablet (extended-release)250 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theolair SR Tab 300mgtablet (extended-release)300 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1979-12-312002-07-09Canada
Theolair SR Tab 500mgtablet (extended-release)500 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theolair Tab 125mgtablet125 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theolair Tab 250mgtablet250 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theophylline 80mg/15mlliquid80 mgoralDesbergers LtÉe, Division Of Technilab Inc.1969-12-311999-09-17Canada
Theophylline Elixirelixir80 mgoralPro Doc Limitee1965-12-312003-07-31Canada
Theophylline Elixirelixir80 mgoralTherapex Division De E Z Em Canada Inc1980-12-311997-04-04Canada
Theophylline Elxelixir80 mgoralTechnilab Pharma Inc.1981-12-312006-07-28Canada
Theophylline In Dextroseinjection, solution80 mg/100mLintravenousBaxter Healthcare Corporation1982-07-26Not applicableUs
Theophylline In Dextroseinjection, solution320 mg/100mLintravenousHospira, Inc.1984-01-02Not applicableUs
Theophylline In Dextroseinjection, solution400 mg/100mLintravenousHospira, Inc.1984-01-02Not applicableUs
Theophylline In Dextroseinjection, solution200 mg/100mLintravenousHospira, Inc.1984-01-02Not applicableUs
Theophylline In Dextroseinjection, solution160 mg/100mLintravenousHospira, Inc.1984-01-02Not applicableUs
Theophylline In Dextroseinjection, solution160 mg/100mLintravenousBaxter Healthcare Corporation1982-07-26Not applicableUs
Theophylline Srt 300mgtablet (extended-release)300 mgoralForest Labs Inc1985-12-311999-05-03Canada
Theophylline Sustained Release Tab 100mgtablet (extended-release)100 mgoralForest Labs Inc1985-12-311999-05-03Canada
Theophylline Sustained Release Tab 200mgtablet (extended-release)200 mgoralForest Labs Inc1985-12-311999-05-03Canada
Uniphyltablet (extended-release)600 mgoralPurdue Pharma1987-12-31Not applicableCanada
Uniphyltablet (extended-release)400 mgoralPurdue Pharma1987-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-theo ERtablet (extended-release)600 mgoralApotex IncNot applicableNot applicableCanada
Apo-theo ERtablet (extended-release)400 mgoralApotex IncNot applicableNot applicableCanada
Apo-theo-LA Srt 100mgtablet (extended-release)100 mgoralApotex Inc1993-12-31Not applicableCanada
Apo-theo-LA Srt 200mgtablet (extended-release)200 mgoralApotex Inc1993-12-31Not applicableCanada
Apo-theo-LA Srt 300mgtablet (extended-release)300 mgoralApotex Inc1993-12-31Not applicableCanada
Elixophyllinliquid80 mg/15mLoralAtlantic Biologicals Corps2009-10-01Not applicableUs
Elixophyllinliquid80 mg/15mLoralCaraco Pharma, Inc.2009-10-01Not applicableUs
Theo-24capsule, extended release100 mg/1oralActient Pharmaceuticals, LLC2014-08-25Not applicableUs
Theo-24capsule, extended release400 mg/1oralUCB, Inc.1998-01-092016-01-07Us
Theo-24capsule, extended release300 mg/1oralUCB, Inc.1998-02-202016-01-07Us
Theo-24capsule, extended release300 mg/1oralCardinal Health1983-08-22Not applicableUs
Theo-24capsule, extended release200 mg/1oralUCB, Inc.1998-01-202016-01-07Us
Theo-24capsule, extended release100 mg/1oralUCB, Inc.1998-04-212016-01-07Us
Theo-24capsule, extended release400 mg/1oralActient Pharmaceuticals, LLC2014-08-25Not applicableUs
Theo-24capsule, extended release300 mg/1oralActient Pharmaceuticals, LLC2014-08-25Not applicableUs
Theo-24capsule, extended release200 mg/1oralActient Pharmaceuticals, LLC2014-08-25Not applicableUs
Theophyllinetablet, extended release200 mg/1oralAv Kare, Inc.2014-12-15Not applicableUs
Theophyllinetablet, extended release300 mg/1oralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
Theophyllinetablet, extended release300 mg/1oralHeritage Pharmaceuticals Inc.2010-11-01Not applicableUs
Theophyllinesolution80 mg/15mLoralPharmaceutical Associates, Inc.2008-11-03Not applicableUs
Theophyllinesolution80 mg/15mLoralLiberta Pharma Inc2013-05-03Not applicableUs
Theophyllinetablet, extended release300 mg/1oralPliva Inc.1990-09-30Not applicableUs
Theophyllinetablet, extended release300 mg/1oralAv Kare, Inc.2014-12-15Not applicableUs
Theophyllinetablet, extended release600 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-07-13Not applicableUs
Theophyllinetablet, extended release200 mg/1oralbryant ranch prepack2010-09-13Not applicableUs
Theophyllinesolution80 mg/15mLoralCranbury Pharmaceuticals Inc2014-11-03Not applicableUs
Theophyllinesolution80 mg/15mLoralSilarx Pharmaceuticals, Inc2011-04-13Not applicableUs
Theophyllinetablet, extended release100 mg/1oralAv Kare, Inc.2014-12-15Not applicableUs
Theophyllinetablet, extended release300 mg/1oralClinical Solutions Wholesale1990-09-30Not applicableUs
Theophyllinetablet, extended release300 mg/1oralA S Medication Solutions Llc1990-09-30Not applicableUs
Theophyllinetablet, extended release300 mg/1oralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Theophyllinetablet, extended release200 mg/1oralREMEDYREPACK INC.2011-04-27Not applicableUs
Theophyllinetablet, extended release300 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Theophyllinetablet, extended release200 mg/1oralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Theophyllinetablet, extended release300 mg/1oralMajor Pharmaceuticals2008-11-13Not applicableUs
Theophyllinetablet, extended release200 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Theophyllinetablet, extended release300 mg/1oralCardinal Health2008-11-13Not applicableUs
Theophyllinetablet, extended release450 mg/1oralAlembic Pharmaceuticals Limited2010-11-01Not applicableUs
Theophyllinetablet, extended release200 mg/1oralCardinal Health2008-11-13Not applicableUs
Theophyllinetablet, extended release200 mg/1oralMajor Pharmaceuticals2008-11-13Not applicableUs
Theophyllinetablet, extended release300 mg/1oralAmerican Health Packaging2015-03-312015-12-29Us
Theophyllinetablet, extended release100 mg/1oralPhysicians Total Care, Inc.2007-07-04Not applicableUs
Theophyllinetablet, extended release100 mg/1oralMajor Pharmaceuticals2008-11-13Not applicableUs
Theophyllinetablet, extended release450 mg/1oralPliva Inc.1993-10-31Not applicableUs
Theophyllinetablet, extended release300 mg/1oralAlembic Pharmaceuticals Limited2010-11-01Not applicableUs
Theophyllinetablet, extended release300 mg/1oralPhysicians Total Care, Inc.2007-09-17Not applicableUs
Theophyllinesolution80 mg/15mLoralMarlex Pharmaceuticals Inc2016-02-01Not applicableUs
Theophyllinesolution80 mg/15mLoralTris Pharma Inc2012-08-02Not applicableUs
Theophyllinetablet, extended release100 mg/1oralPliva Inc.1990-09-30Not applicableUs
Theophyllinetablet, extended release200 mg/1oralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
Theophyllinetablet, extended release300 mg/1oralbryant ranch prepack1990-09-30Not applicableUs
Theophyllinetablet, extended release200 mg/1oralPhysicians Total Care, Inc.1996-12-19Not applicableUs
Theophyllinetablet, extended release450 mg/1oralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
Theophyllinetablet, extended release450 mg/1oralHeritage Pharmaceuticals Inc.2010-11-01Not applicableUs
Theophyllinetablet, extended release200 mg/1oralPliva Inc.1990-09-30Not applicableUs
Theophyllinetablet, extended release400 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-07-13Not applicableUs
Theophyllinetablet, extended release100 mg/1oralbryant ranch prepack1990-09-30Not applicableUs
Theophylline (anhydrous)tablet, extended release600 mg/1oralCarilion Materials Management2007-06-01Not applicableUs
Theophylline (anhydrous)tablet, extended release300 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Theophylline (anhydrous)tablet, extended release200 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Theophylline (anhydrous)tablet, extended release600 mg/1oralNostrum Laboratories, Inc.2007-06-01Not applicableUs
Theophylline (anhydrous)tablet, extended release400 mg/1oralNostrum Laboratories, Inc.2007-06-01Not applicableUs
Theophylline Anhydroustablet, extended release400 mg/1oralCarilion Materials Management2012-02-02Not applicableUs
Theophylline Anhydroustablet, extended release600 mg/1oralRhodes Pharmaceuticals L.P.2012-02-02Not applicableUs
Theophylline Anhydroustablet, extended release400 mg/1oralRhodes Pharmaceuticals L.P.2012-02-02Not applicableUs
Theophylline Extended Releasetablet300 mg/1oralREMEDYREPACK INC.2011-07-07Not applicableUs
Theophylline Extended Releasetablet, extended release200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-04-30Not applicableUs
Theophylline Extended Releasetablet, extended release300 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-04-30Not applicableUs
Theophylline(anhydrous)tablet, extended release400 mg/1oralPACK Pharmaceuticals, LLC2010-09-15Not applicableUs
Uniphyltablet600 mg/1oralPurdue Pharmaceutical Products LP1996-06-07Not applicableUs
Uniphyltablet400 mg/1oralPurdue Pharmaceutical Products LP1982-09-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Quibron-TNot Available
RespbidNot Available
Slo-BidNot Available
Theo 24Not Available
Theo-DurNot Available
Theodur GNot Available
Brand mixtures
NameLabellerIngredients
I D M Expectorant TabRougier Pharma Division Of Ratiopharm Inc
Idm TabRougier Pharma Division Of Ratiopharm Inc
Ratio-theo-broncRatiopharm Inc Division Of Teva Canada Limited
SenophyllinePhysician Therapeutics Llc
Tedral TabParke Davis Division, Warner Lambert Canada Inc.
Theophylline 0.8mg and 5% Dextrose InjBaxter Corporation
Theophylline 0.8mg/ml In 5% Dextrose InjHospira Healthcare Corporation
Theophylline 1.6mg and 5% Dextrose InjBaxter Corporation
Theophylline 4mg and 5% Dextrose InjBaxter Corporation
Theophylline In DextroseB. Braun Medical Inc.
Theophylline Rougier ElixirRougier Pharma Division Of Ratiopharm Inc
Salts
Name/CASStructureProperties
Theophylline sodium glycinate
8000-10-0
Thumb
  • InChI Key: AIJQWRAOMFRHTQ-UHFFFAOYSA-M
  • Monoisotopic Mass: 277.07869817
  • Average Mass: 277.216
DBSALT001603
Categories
UNII0I55128JYK
CAS number58-55-9
WeightAverage: 180.164
Monoisotopic: 180.06472552
Chemical FormulaC7H8N4O2
InChI KeyInChIKey=ZFXYFBGIUFBOJW-UHFFFAOYSA-N
InChI
InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
IUPAC Name
1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
CN1C2=C(NC=N2)C(=O)N(C)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alkaloids and derivatives. These are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic properties. Also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassNot Available
Sub ClassNot Available
Direct ParentAlkaloids and derivatives
Alternative Parents
Substituents
  • Alkaloid or derivatives
  • Xanthine
  • Purinone
  • 6-oxopurine
  • Purine
  • Imidazopyrimidine
  • Pyrimidone
  • Pyrimidine
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azole
  • Urea
  • Lactam
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
PharmacodynamicsTheophylline, an xanthine derivative chemically similar to caffeine and theobromine, is used to treat asthma and bronchospasm. Theophylline has two distinct actions in the airways of patients with reversible (asthmatic) obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects).
Mechanism of actionTheophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.
Related Articles
AbsorptionTheophylline is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form.
Volume of distribution
  • 0.3 to 0.7 L/kg
Protein binding40%, primarily to albumin.
Metabolism

Hepatic. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N-methylated to caffeine. Caffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity.

SubstrateEnzymesProduct
Theophylline
1-MethylxanthineDetails
Theophylline
3-methylxanthineDetails
Theophylline
1,3-dimethyluric acidDetails
Theophylline
Not Available
CaffeineDetails
Route of eliminationTheophylline does not undergo any appreciable pre-systemic elimination, distributes freely into fat-free tissues and is extensively metabolized in the liver. Renal excretion of unchanged theophylline in neonates amounts to about 50% of the dose, compared to about 10% in children older than three months and in adults.
Half life8 hours
Clearance
  • 0.29 mL/kg/min [Premature neonates, postnatal age 3-15 days]
  • 0.64 mL/kg/min [Premature neonates, postnatal age 25-57 days]
  • 1.7 mL/kg/min [Children 1-4 years]
  • 1.6 mL/kg/min [Children 4-12 years]
  • 0.9 mL/kg/min [Children 13-15 years]
  • 1.4 mL/kg/min [Children 16-17 years]
  • 0.65 mL/kg/min [Adults (16-60 years), otherwise healthy non-smoking asthmatics]
  • 0.41 mL/kg/min [Elderly (>60 years), non-smokers with normal cardiac, liver, and renal function]
  • 0.33 mL/kg/min [Acute pulmonary edema]
  • 0.54 mL/kg/min [COPD >60 years, stable, non-smoker >1 year]
  • 0.48 mL/kg/min [COPD with cor pulmonale]
  • 1.25 mL/kg/min [Cystic fibrosis (14-28 years)]
  • 0.31 mL/kg/min [Liver disease cirrhosis]
  • 0.35 mL/kg/min [acute hepatitis]
  • 0.65 mL/kg/min [cholestasis]
  • 0.47 mL/kg/min [Sepsis with multi-organ failure]
  • 0.38 mL/kg/min [hypothyroid]
  • 0.8 mL/kg/min [hyperthyroid]
ToxicitySymptoms of overdose include seizures, arrhythmias, and GI effects.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Caffeine MetabolismMetabolicSMP00028
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 1A2
Gene symbol: CYP1A2
UniProt: P05177
Not Available-2964(G/A)A AllelePoor metabolizer, lower dose requirement12732846
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9902
Caco-2 permeable+0.6172
P-glycoprotein substrateNon-substrate0.7281
P-glycoprotein inhibitor INon-inhibitor0.8939
P-glycoprotein inhibitor IINon-inhibitor0.911
Renal organic cation transporterNon-inhibitor0.8807
CYP450 2C9 substrateNon-substrate0.7738
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.5974
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9933
CYP450 2D6 inhibitorNon-inhibitor0.9827
CYP450 2C19 inhibitorNon-inhibitor0.9895
CYP450 3A4 inhibitorNon-inhibitor0.9616
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9956
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9447
BiodegradationReady biodegradable0.5942
Rat acute toxicity2.7898 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8819
hERG inhibition (predictor II)Non-inhibitor0.8927
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Fleming and co pharmaceuticals inc
  • Forest laboratories inc
  • Sanofi aventis us llc
  • Dm graham laboratories inc
  • Ucb inc
  • Whitby pharmaceuticals inc
  • Schwarz pharma inc
  • Schering corp
  • Central pharmaceuticals inc
  • Hospira inc
  • Inwood laboratories inc sub forest laboratories inc
  • Sandoz inc
  • Rp scherer north america div rp scherer corp
  • Ortho mcneil pharmaceutical inc
  • Schering corp sub schering plough corp
  • Fisons corp
  • Kv pharmaceutical co
  • Rp scherer north america
  • Hr cenci laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Lannett co inc
  • Panray corp sub ormont drug and chemical co inc
  • Alpharma us pharmaceuticals division
  • Cenci powder products inc
  • Halsey drug co inc
  • L perrigo co
  • Pharmaceutical assoc inc div beach products
  • Precision dose inc
  • Roxane laboratories inc
  • Taro pharmaceuticals usa inc
  • Wockhardt eu operations (swiss) ag
  • B braun medical inc
  • Baxter healthcare corp
  • 3m pharmaceuticals inc
  • Ferndale laboratories inc
  • Warner chilcott co llc
  • Monarch pharmaceuticals inc
  • Roerig div pfizer inc
  • Able laboratories inc
  • Glenmark generics ltd
  • Nostrum pharmaceuticals inc
  • Pliva inc
  • Pharmaceutical research assoc inc
  • Purdue pharmaceutical products lp
  • Graceway pharmaceuticals llc
  • Novartis consumer health inc
Packagers
Dosage forms
FormRouteStrength
Tablet (extended-release)oral100 mg
Tablet (extended-release)oral200 mg
Tablet (extended-release)oral300 mg
Liquidoral80 mg/15mL
Tabletoral
Elixiroral80 mg
Syruporal
Kit
Capsule (sustained-release)oral100 mg
Capsule (sustained-release)oral200 mg
Capsule (sustained-release)oral300 mg
Capsule (sustained-release)oral50 mg
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral300 mg/1
Capsule, extended releaseoral400 mg/1
Tablet (extended-release)oral450 mg
Liquidoral80 mg
Tablet (extended-release)oral250 mg
Tablet (extended-release)oral500 mg
Tabletoral125 mg
Tabletoral250 mg
Solutionoral80 mg/15mL
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral450 mg/1
Tablet, extended releaseoral600 mg/1
Solutionintravenous
Tabletoral300 mg/1
Tablet, extended releaseoral200 mg/1
Tablet, extended releaseoral300 mg/1
Injection, solutionintravenous
Injection, solutionintravenous160 mg/100mL
Injection, solutionintravenous200 mg/100mL
Injection, solutionintravenous320 mg/100mL
Injection, solutionintravenous400 mg/100mL
Injection, solutionintravenous80 mg/100mL
Elixiroral
Tablet, extended releaseoral400 mg/1
Tabletoral400 mg/1
Tabletoral600 mg/1
Tablet (extended-release)oral400 mg
Tablet (extended-release)oral600 mg
Prices
Unit descriptionCostUnit
Elixophyllin GG 100-100 mg/15ml Solution 240ml Bottle60.98USD bottle
Uniphyl 600 mg 24 Hour tablet2.28USD tablet
Theo-24 400 mg 24 Hour Capsule2.04USD capsule
Theo-24 400 mg capsule sa1.97USD capsule
Uniphyl 400 mg 24 Hour tablet1.58USD tablet
Theo-24 300 mg 24 Hour Capsule1.45USD capsule
Theo-24 300 mg capsule sa1.4USD capsule
Theophylline 400 mg 24 Hour tablet1.27USD tablet
Theo-24 200 mg 24 Hour Capsule1.25USD capsule
Theo-24 200 mg capsule sa1.14USD capsule
Theochron 450 mg tablet sa0.94USD tablet
Theophylline CR 300 mg 12 Hour Capsule0.93USD capsule
Theo-24 100 mg 24 Hour Capsule0.83USD capsule
Theophylline CR 200 mg 12 Hour Capsule0.79USD capsule
Theophylline CR 450 mg 12 Hour tablet0.79USD tablet
Theo-24 100 mg capsule sa0.76USD capsule
Quibron 90-150 mg capsule0.73USD capsule
Theophylline CR 125 mg 12 Hour Capsule0.73USD capsule
Uniphyl 600 mg Sustained-Release Tablet0.68USD tablet
Uniphyl 400 mg Sustained-Release Tablet0.56USD tablet
Theochron 300 mg tablet sa0.54USD tablet
Theophylline CR 300 mg 12 Hour tablet0.51USD tablet
Theophylline CR 200 mg 12 Hour tablet0.4USD tablet
Theochron 200 mg tablet sa0.33USD tablet
Theophylline CR 100 mg 12 Hour tablet0.3USD tablet
Elixophyllin GG 100-100 mg/15ml Solution0.24USD ml
Theochron 100 mg tablet sa0.23USD tablet
Elixophyllin 80 mg/15ml Elixir0.2USD ml
Elixophyllin 80 mg/15 ml elix0.19USD ml
Apo-Theo La 300 mg Sustained-Release Tablet0.15USD tablet
Apo-Theo La 100 mg Sustained-Release Tablet0.14USD tablet
Apo-Theo La 200 mg Sustained-Release Tablet0.14USD tablet
Theophylline anhydrous powder0.08USD g
Theophylline 200 mg/100 ml d5w0.06USD ml
Theolair 5.3 mg/ml Liquid0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point273 °CPhysProp
water solubility7360 mg/L (at 25 °C)YALKOWSKY,SH & HE,Y (2003)
logP-0.02HANSCH,C ET AL. (1995)
Caco2 permeability-4.35ADME Research, USCD
pKa8.81KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility22.9 mg/mLALOGPS
logP-0.26ALOGPS
logP-0.77ChemAxon
logS-0.9ALOGPS
pKa (Strongest Acidic)7.82ChemAxon
pKa (Strongest Basic)-0.78ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area69.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity44.93 m3·mol-1ChemAxon
Polarizability16.86 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (2.96 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (1 TMS)splash10-0f79-6970000000-224461ad62a44dbdf860View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-00di-0900000000-0092516012d6a2a93b31View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-00di-4900000000-dcf52c18a6996f412b1aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-00kf-9000000000-09089337909892ef44cbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (Unknown) , Positivesplash10-001j-7900000000-a08735d528e738752429View in MoNA
LC-MS/MSLC-MS/MS Spectrum - CI-B (Unknown) , Positivesplash10-001i-0900000000-d0882f7d959c726e7623View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-004i-0900000000-c4943571126a44bb9e5aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-004i-0900000000-bc12ce29acd02fa749b8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-03k9-0900000000-d63f60043f186fbb9bc0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-070l-4900000000-d293ab2fa6199dbaf97aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-05ru-9400000000-dde4775588d52c83806fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-004i-0900000000-556e382f583d610ef1f0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-004i-0900000000-89e34f5158856ba33469View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-03k9-0900000000-65a6897d72954e875b00View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-070l-4900000000-df16604bd6c40cee8f24View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-05r3-9500000000-39a721dcecc86ed95507View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-001i-1900000000-e67ff7ef9a955b90eb3fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-001i-3900000000-1870952d98dbba22ace8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-00di-7900000000-dc0e9606776c43a7823fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-014j-9300000000-2c4c6490dda3ed3b563fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-014i-9000000000-26a6c0c23a465afdcde1View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-01q9-1900000000-b11ca3441bb29fef1906View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-0002-9400000000-63726fe0b49a9dc6ba7eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-00di-9100000000-139f765bc9b5855960c6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-00di-9000000000-88b5cb393b960973ac64View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-00yi-9000000000-1ebbddce3c7133972546View in MoNA
MSMass Spectrum (Electron Ionization)splash10-00lr-9500000000-2c8464c2fe84464c207fView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Nicolae S. Bodor, Kenneth B. Sloan, Yu-Neng Kuo, “Method for synthesizing certain selected pro-drug forms of theophylline.” U.S. Patent US4000132, issued January, 1956.

US4000132
General ReferencesNot Available
External Links
ATC CodesR03DA04R03DA54R03DA74R03DB04
AHFS Codes
  • 86:16.00
PDB EntriesNot Available
FDA labelDownload (85.2 KB)
MSDSDownload (75.1 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Theophylline can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Theophylline.
AcetaminophenThe serum concentration of Theophylline can be decreased when it is combined with Acetaminophen.
AdalimumabThe serum concentration of Theophylline can be decreased when it is combined with Adalimumab.
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Theophylline.
AllopurinolThe serum concentration of Theophylline can be increased when it is combined with Allopurinol.
AlprazolamThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Theophylline.
AmobarbitalThe serum concentration of Theophylline can be decreased when it is combined with Amobarbital.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Theophylline.
AprepitantThe serum concentration of Theophylline can be increased when it is combined with Aprepitant.
AtenololAtenolol may decrease the activities of Theophylline.
AtomoxetineAtomoxetine may increase the hypertensive activities of Theophylline.
BatimastatThe serum concentration of Theophylline can be decreased when it is combined with Batimastat.
BendroflumethiazideBendroflumethiazide may decrease the activities of Theophylline.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Theophylline.
BetaxololBetaxolol may decrease the activities of Theophylline.
BexaroteneThe serum concentration of Theophylline can be decreased when it is combined with Bexarotene.
BisoprololBisoprolol may decrease the activities of Theophylline.
BortezomibThe metabolism of Theophylline can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Theophylline can be decreased when it is combined with Bosentan.
BromazepamThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Theophylline.
ButabarbitalThe serum concentration of Theophylline can be decreased when it is combined with Butabarbital.
ButalbitalThe serum concentration of Theophylline can be decreased when it is combined with Butalbital.
ButethalThe serum concentration of Theophylline can be decreased when it is combined with Butethal.
CaffeineThe serum concentration of Theophylline can be decreased when it is combined with Caffeine.
CalcidiolThe serum concentration of Theophylline can be increased when it is combined with Calcidiol.
CalcitriolThe serum concentration of Theophylline can be increased when it is combined with Calcitriol.
CamazepamThe therapeutic efficacy of Camazepam can be decreased when used in combination with Theophylline.
CarbamazepineThe serum concentration of Theophylline can be decreased when it is combined with Carbamazepine.
CarbimazoleThe serum concentration of Theophylline can be increased when it is combined with Carbimazole.
CarteololCarteolol may decrease the activities of Theophylline.
CarvedilolCarvedilol may decrease the activities of Theophylline.
ChlordiazepoxideThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Theophylline.
ChlormezanoneThe therapeutic efficacy of Chlormezanone can be decreased when used in combination with Theophylline.
ChlorotrianiseneThe serum concentration of Theophylline can be increased when it is combined with Chlorotrianisene.
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Theophylline.
CholecalciferolThe serum concentration of Theophylline can be increased when it is combined with Cholecalciferol.
CimetidineThe metabolism of Theophylline can be decreased when combined with Cimetidine.
CinolazepamThe therapeutic efficacy of Cinolazepam can be decreased when used in combination with Theophylline.
CiprofloxacinThe metabolism of Theophylline can be decreased when combined with Ciprofloxacin.
ClarithromycinThe metabolism of Theophylline can be decreased when combined with Clarithromycin.
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Theophylline.
ClidiniumThe therapeutic efficacy of Clidinium can be decreased when used in combination with Theophylline.
ClobazamThe therapeutic efficacy of Clobazam can be decreased when used in combination with Theophylline.
ClonazepamThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Theophylline.
ClorazepateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Theophylline.
ClotiazepamThe therapeutic efficacy of Clotiazepam can be decreased when used in combination with Theophylline.
CloxazolamThe therapeutic efficacy of Cloxazolam can be decreased when used in combination with Theophylline.
ConivaptanThe serum concentration of Theophylline can be increased when it is combined with Conivaptan.
Cyproterone acetateThe serum concentration of Theophylline can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Theophylline can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Theophylline can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Theophylline can be increased when it is combined with Deferasirox.
DesogestrelThe serum concentration of Theophylline can be increased when it is combined with Desogestrel.
DiazepamThe therapeutic efficacy of Diazepam can be decreased when used in combination with Theophylline.
DihydrotachysterolThe serum concentration of Theophylline can be increased when it is combined with Dihydrotachysterol.
DisulfiramThe serum concentration of Theophylline can be increased when it is combined with Disulfiram.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Theophylline.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Theophylline.
DoxofyllineThe risk or severity of adverse effects can be increased when Theophylline is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Theophylline.
DrospirenoneThe serum concentration of Theophylline can be increased when it is combined with Drospirenone.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Theophylline.
ErgocalciferolThe serum concentration of Theophylline can be increased when it is combined with Ergocalciferol.
ErythromycinThe metabolism of Theophylline can be decreased when combined with Erythromycin.
EsmololEsmolol may decrease the activities of Theophylline.
EstazolamThe therapeutic efficacy of Estazolam can be decreased when used in combination with Theophylline.
EstradiolThe serum concentration of Theophylline can be increased when it is combined with Estradiol.
Estrone sulfateThe serum concentration of Theophylline can be increased when it is combined with Estropipate.
EthanolThe serum concentration of Theophylline can be increased when it is combined with Ethanol.
Ethinyl EstradiolThe serum concentration of Theophylline can be increased when it is combined with Ethinyl Estradiol.
Ethynodiol diacetateThe serum concentration of Theophylline can be increased when it is combined with Ethynodiol.
FebuxostatThe serum concentration of the active metabolites of Theophylline can be increased when Theophylline is used in combination with Febuxostat.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Theophylline.
FluconazoleThe metabolism of Theophylline can be decreased when combined with Fluconazole.
FludiazepamThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Theophylline.
FlunitrazepamThe therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Theophylline.
FlurazepamThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Theophylline.
FluvoxamineThe metabolism of Theophylline can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Theophylline is combined with Formoterol.
FosaprepitantThe serum concentration of Theophylline can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Theophylline can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Theophylline can be increased when it is combined with Fusidic Acid.
HalazepamThe therapeutic efficacy of Halazepam can be decreased when used in combination with Theophylline.
HeptabarbitalThe serum concentration of Theophylline can be decreased when it is combined with Heptabarbital.
HexobarbitalThe serum concentration of Theophylline can be decreased when it is combined with Hexobarbital.
IdelalisibThe serum concentration of Theophylline can be increased when it is combined with Idelalisib.
IndacaterolThe risk or severity of adverse effects can be increased when Theophylline is combined with Indacaterol.
Interferon alfa-n3The metabolism of Theophylline can be decreased when combined with Interferon alfa-n3.
Interferon alfacon-1The metabolism of Theophylline can be decreased when combined with Interferon alfacon-1.
Interferon beta-1aThe metabolism of Theophylline can be decreased when combined with Interferon beta-1a.
Interferon beta-1bThe metabolism of Theophylline can be decreased when combined with Interferon beta-1b.
Interferon gamma-1bThe metabolism of Theophylline can be decreased when combined with Interferon gamma-1b.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Theophylline.
IsoflurophateThe serum concentration of Theophylline can be decreased when it is combined with Isoflurophate.
IsoniazidThe serum concentration of Theophylline can be increased when it is combined with Isoniazid.
IsoprenalineThe serum concentration of Theophylline can be decreased when it is combined with Isoprenaline.
IvacaftorThe serum concentration of Theophylline can be increased when it is combined with Ivacaftor.
KetazolamThe therapeutic efficacy of Ketazolam can be decreased when used in combination with Theophylline.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Theophylline.
LevobunololLevobunolol may decrease the activities of Theophylline.
LevothyroxineThe metabolism of Theophylline can be increased when combined with Levothyroxine.
LinezolidLinezolid may increase the hypertensive activities of Theophylline.
LiothyronineThe metabolism of Theophylline can be increased when combined with Liothyronine.
LiotrixThe metabolism of Theophylline can be increased when combined with Liotrix.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Theophylline.
LorazepamThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Theophylline.
LuliconazoleThe serum concentration of Theophylline can be increased when it is combined with Luliconazole.
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Theophylline.
MestranolThe serum concentration of Theophylline can be increased when it is combined with Mestranol.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Theophylline.
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Theophylline.
MethimazoleThe serum concentration of Theophylline can be increased when it is combined with Methimazole.
MethohexitalThe serum concentration of Theophylline can be decreased when it is combined with Methohexital.
MethotrexateThe serum concentration of Theophylline can be increased when it is combined with Methotrexate.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Theophylline.
MetipranololMetipranolol may decrease the activities of Theophylline.
MetoprololMetoprolol may decrease the activities of Theophylline.
MetreleptinThe serum concentration of Theophylline can be decreased when it is combined with Metreleptin.
MexiletineThe metabolism of Theophylline can be decreased when combined with Mexiletine.
MidazolamThe therapeutic efficacy of Midazolam can be decreased when used in combination with Theophylline.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Theophylline.
MifepristoneThe serum concentration of Theophylline can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Theophylline can be decreased when it is combined with Mitotane.
NadololNadolol may decrease the activities of Theophylline.
NaphazolineThe risk or severity of adverse effects can be increased when Naphazoline is combined with Theophylline.
NebivololNebivolol may decrease the activities of Theophylline.
NelfinavirThe metabolism of Theophylline can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Theophylline can be increased when it is combined with Netupitant.
NitrazepamThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Theophylline.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Theophylline.
NorethisteroneThe serum concentration of Theophylline can be increased when it is combined with Norethindrone.
NorfloxacinThe metabolism of Theophylline can be decreased when combined with Norfloxacin.
NorgestimateThe serum concentration of Theophylline can be increased when it is combined with Norgestimate.
OfloxacinThe metabolism of Theophylline can be decreased when combined with Ofloxacin.
OlodaterolThe risk or severity of adverse effects can be increased when Theophylline is combined with Olodaterol.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Theophylline.
OxazepamThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Theophylline.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Theophylline.
PalbociclibThe serum concentration of Theophylline can be increased when it is combined with Palbociclib.
PancuroniumThe risk or severity of adverse effects can be increased when Theophylline is combined with Pancuronium.
Peginterferon alfa-2aThe metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a.
Peginterferon alfa-2bThe serum concentration of Theophylline can be increased when it is combined with Peginterferon alfa-2b.
Peginterferon beta-1aThe metabolism of Theophylline can be decreased when combined with Peginterferon beta-1a.
PenbutololPenbutolol may decrease the activities of Theophylline.
PentobarbitalThe serum concentration of Theophylline can be decreased when it is combined with Pentobarbital.
PentoxifyllineThe serum concentration of Theophylline can be increased when it is combined with Pentoxifylline.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Theophylline.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Theophylline.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Theophylline.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Theophylline.
PhenytoinThe serum concentration of Theophylline can be decreased when it is combined with Phenytoin.
PindololPindolol may decrease the activities of Theophylline.
Potassium IodideThe serum concentration of Theophylline can be increased when it is combined with Potassium Iodide.
PrimidoneThe serum concentration of Theophylline can be decreased when it is combined with Primidone.
PropafenoneThe serum concentration of Theophylline can be increased when it is combined with Propafenone.
PropranololPropranolol may decrease the activities of Theophylline.
PropylthiouracilThe serum concentration of Theophylline can be increased when it is combined with Propylthiouracil.
QuazepamThe therapeutic efficacy of Quazepam can be decreased when used in combination with Theophylline.
QuinineThe serum concentration of Theophylline can be increased when it is combined with Quinine.
RegadenosonTheophylline may decrease the vasodilatory activities of Regadenoson.
RiociguatTheophylline may increase the hypotensive activities of Riociguat.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Theophylline.
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Theophylline.
SecobarbitalThe serum concentration of Theophylline can be decreased when it is combined with Secobarbital.
SiltuximabThe serum concentration of Theophylline can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Theophylline can be increased when it is combined with Simeprevir.
SotalolSotalol may decrease the activities of Theophylline.
St. John's WortThe serum concentration of Theophylline can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Theophylline can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Theophylline can be decreased when combined with Sulfisoxazole.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Theophylline.
TemazepamThe therapeutic efficacy of Temazepam can be decreased when used in combination with Theophylline.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Theophylline.
TeriflunomideThe serum concentration of Theophylline can be decreased when it is combined with Teriflunomide.
ThiabendazoleThe metabolism of Theophylline can be decreased when combined with Thiabendazole.
Thyroid, porcineThe metabolism of Theophylline can be increased when combined with Thyroid extract.
TiclopidineThe metabolism of Theophylline can be decreased when combined with Ticlopidine.
TimololTimolol may decrease the activities of Theophylline.
TipranavirThe serum concentration of Theophylline can be decreased when it is combined with Tipranavir.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Theophylline.
TocilizumabThe serum concentration of Theophylline can be decreased when it is combined with Tocilizumab.
TofisopamThe therapeutic efficacy of Tofisopam can be decreased when used in combination with Theophylline.
TriazolamThe therapeutic efficacy of Triazolam can be decreased when used in combination with Theophylline.
VemurafenibThe serum concentration of Theophylline can be increased when it is combined with Vemurafenib.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Theophylline.
ZileutonThe serum concentration of Theophylline can be increased when it is combined with Zileuton.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Purine nucleoside binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
ADORA1
Uniprot ID:
P30542
Molecular Weight:
36511.325 Da
References
  1. Nantwi KD, Basura GJ, Goshgarian HG: Adenosine A1 receptor mRNA expression and the effects of systemic theophylline administration on respiratory function 4 months after C2 hemisection. J Spinal Cord Med. 2003 Winter;26(4):364-71. [PubMed:14992338 ]
  2. Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. [PubMed:3588607 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Identical protein binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
ADORA2A
Uniprot ID:
P29274
Molecular Weight:
44706.925 Da
References
  1. Pechlivanova DM, Georgiev VP: Effects of single and long-term theophylline treatment on the threshold of mechanical nociception: contribution of adenosine A1 and alpha2-adrenoceptors. Methods Find Exp Clin Pharmacol. 2005 Nov;27(9):659-64. [PubMed:16357952 ]
  2. Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. [PubMed:3588607 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled adenosine receptor activity
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
ADORA2B
Uniprot ID:
P29275
Molecular Weight:
36332.655 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV: Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res. 2006 May 1;70(2):308-14. Epub 2006 Feb 23. [PubMed:16545350 ]
  3. Phelps PT, Anthes JC, Correll CC: Characterization of adenosine receptors in the human bladder carcinoma T24 cell line. Eur J Pharmacol. 2006 Apr 24;536(1-2):28-37. Epub 2006 Mar 3. [PubMed:16581066 ]
  4. Fozard JR, Baur F, Wolber C: Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog. Eur J Pharmacol. 2003 Aug 15;475(1-3):79-84. [PubMed:12954362 ]
  5. Holgate ST: The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol. 2005 Aug;145(8):1009-15. [PubMed:15980878 ]
  6. Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. [PubMed:3588607 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.
Gene Name:
PDE4B
Uniprot ID:
Q07343
Molecular Weight:
83342.695 Da
References
  1. Lipworth BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005 Jan 8-14;365(9454):167-75. [PubMed:15639300 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).
Gene Name:
PDE5A
Uniprot ID:
O76074
Molecular Weight:
99984.14 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4A
Uniprot ID:
P27815
Molecular Weight:
98142.155 Da
References
  1. Wang K, Chen JQ, Chen Z, Chen JC: Inhibition of human phosphodiesterase 4A expressed in yeast cell GL62 by theophylline, rolipram, and acetamide-45. Acta Pharmacol Sin. 2002 Nov;23(11):1013-7. [PubMed:12421478 ]
  2. Haider S: Cyclic AMP level and phosphodiesterase activity during 17alpha,20beta-dihydroxy-4-pregnen-3-one induction and theophylline inhibition of oocyte maturation in the catfish, Clarias batrachus. Comp Biochem Physiol A Mol Integr Physiol. 2003 Feb;134(2):267-74. [PubMed:12547256 ]
  3. Rickards KJ, Andrews MJ, Waterworth TH, Alexander GB, Cunningham FM: Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther. 2003 Aug;26(4):277-82. [PubMed:12887610 ]
  4. Usta C, Sadan G, Tuncel B: The effect of the indomethacin on phosphodiesterase inhibitors mediated responses in isolated trachea preparations. Prostaglandins Leukot Essent Fatty Acids. 2004 Sep;71(3):137-41. [PubMed:15253881 ]
  5. Lee JM, Zemans RL, Hejazi M, Chin BB, Ladenson PW, Caturegli P: Modulation of thyroidal radioiodine uptake by theophylline. Exp Mol Pathol. 2004 Oct;77(2):116-20. [PubMed:15351234 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
Gene Name:
PDE3A
Uniprot ID:
Q14432
Molecular Weight:
124978.06 Da
References
  1. Rickards KJ, Andrews MJ, Waterworth TH, Alexander GB, Cunningham FM: Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther. 2003 Aug;26(4):277-82. [PubMed:12887610 ]
  2. Wu BN, Lin RJ, Lo YC, Shen KP, Wang CC, Lin YT, Chen IJ: KMUP-1, a xanthine derivative, induces relaxation of guinea-pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels. Br J Pharmacol. 2004 Aug;142(7):1105-14. Epub 2004 Jul 5. [PubMed:15237094 ]
  3. Kajikawa S, Kigami D, Nakayama H, Doi K: Changes in submaxillary gland gene expression in F344 rats by multiple dosing of theophylline. Exp Anim. 2006 Apr;55(2):143-6. [PubMed:16651698 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
activator
General Function:
Transcription factor binding
Specific Function:
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Forms transcriptional repressor c...
Gene Name:
HDAC2
Uniprot ID:
Q92769
Molecular Weight:
55363.855 Da
References
  1. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8921-6. Epub 2002 Jun 17. [PubMed:12070353 ]
  2. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ: Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004 Sep 6;200(5):689-95. Epub 2004 Aug 30. [PubMed:15337792 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  2. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Sarkar MA, Hunt C, Guzelian PS, Karnes HT: Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos. 1992 Jan-Feb;20(1):31-7. [PubMed:1346993 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Zinc ion binding
Specific Function:
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.
Gene Name:
ADA
Uniprot ID:
P00813
Molecular Weight:
40764.13 Da
References
  1. Saboury AA, Bagheri S, Ataie G, Amanlou M, Moosavi-Movahedi AA, Hakimelahi GH, Cristalli G, Namaki S: Binding properties of adenosine deaminase interacted with theophylline. Chem Pharm Bull (Tokyo). 2004 Oct;52(10):1179-82. [PubMed:15467230 ]
  2. Singh LS, Sharma R: Purification and characterization of intestinal adenosine deaminase from mice. Mol Cell Biochem. 2000 Jan;204(1-2):127-34. [PubMed:10718633 ]
  3. Bandyopadhyay BC, Poddar MK: Theophylline-induced changes in mammalian adenosine deaminase activity and corticosterone status: possible relation to immune response. Methods Find Exp Clin Pharmacol. 1997 Apr;19(3):181-4. [PubMed:9203166 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Sarkar MA, Hunt C, Guzelian PS, Karnes HT: Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos. 1992 Jan-Feb;20(1):31-7. [PubMed:1346993 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T: Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. Epub 2005 Feb 11. [PubMed:15708966 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 02, 2016 16:08